目的:观察一清双解胶囊和片剂治疗急性上呼吸道感染(风温病热在肺卫证)的疗效,并对其安全性作出评价。方法:采用多中心随机对照双盲双模拟试验,对急性上呼吸道感染(风温病热在肺卫证)患者360例,按1∶1∶1比例随机分为一清双解胶囊组(治...目的:观察一清双解胶囊和片剂治疗急性上呼吸道感染(风温病热在肺卫证)的疗效,并对其安全性作出评价。方法:采用多中心随机对照双盲双模拟试验,对急性上呼吸道感染(风温病热在肺卫证)患者360例,按1∶1∶1比例随机分为一清双解胶囊组(治疗组A)120例,一清双解片剂组(治疗组B)120例及柴黄片组(对照组)120例。治疗组分别给予一清双解胶囊或片剂,每次3粒(片),每日3次;对照组给予柴黄片,每次3片,每日3次。疗程均为5d。观察治疗前后症状、体征变化和有无不良反应,并进行血、尿、大便常规,肝肾功能及心电图检查。结果:纳入患者360例,剔除3例,脱落18例,最终进入意向性(intention-to-treat,ITT)分析343例,符合方案集(per-protocol population set,PPS)分析339例。其中上呼吸道感染疗效:ITT显示,治疗组A总显效率84.96%,总有效率为96.46%;治疗组B分别为85.48%,97.45%;对照组分别为72.58%,99.12%。PPS显示,治疗组A总显效率87.27%,总有效率97.27%;治疗组B分别为86.20%,97.41%;对照组分别为72.58%,99.12%。试验组(胶囊、片剂)疾病疗效优于对照组(P<0.05),ITT与PPS结果一致。中医证候疗效:ITT显示,治疗组A愈显率84.07%,总有效率96.46%;治疗组B分别为88.89%,97.44%;对照组分别为72.58%,99.12%。PPS显示,治疗组A愈显率85.46%,总有效率97.27%;治疗组B分别为89.65%,97.41%;对照组分别为72.58%,99.12%。试验组(胶囊、片剂)中医证候疗效优于对照组(P<0.05),ITT与PPS结果一致。观察中未发现明显不良反应。结论:一清双解胶囊和片剂治疗急性上呼吸道感染热在肺卫证疗效确切,未发现明显毒副作用。展开更多
Thirty-one herbal preparations produced and sold on the Ghanaian market were randomly purchased from sales outlets and analyzed for their microbiological quality by testing for the presence of total coliform bacteria,...Thirty-one herbal preparations produced and sold on the Ghanaian market were randomly purchased from sales outlets and analyzed for their microbiological quality by testing for the presence of total coliform bacteria, faecal coliform bac- teria, and total heterotrophic bacteria count. Also tested for was detection of pathogenic bacteria such as the Salmonella spp. and Clostridium spp. Opportunistic bacterial pathogens (Aeromonas spp., Enterococcus spp. and Pseudomonas spp.) and mould were also tested for. The herbal preparations tested came from different processing companies and in- cluded those labeled as suitable for treating arthritis, asthma, anaemia, diabetes mellitus, epilepsy, cough, hypertension, dysmenorrhoea, malaria, urine retention and loss of appetite. Aliquots of the various herbal products were cultured on various selective media. Eight (8) of the products showed the presence of all microorganism analyzed for including the pathogenic ones and are recommended not be used. Five (5) of the products did not have any microorganism present. Eleven (11) products showed the presence of only total heterotrophic bacteria and the values ranged from 1 to 94 cfu per ml. These two groups of total of sixteen (16) products can be used without any microbiological risk. Another three (3) products showed presence of only total heterotrophic bacteria but the values ranged from 118 to 1648 cfu per ml. Majority of the herbal preparations showed the presence of pathogenic bacteria. These three products may pose danger to the user can be used with caution. None of the herbal products recorded the presence of Enterococcus spp.展开更多
文摘目的:观察一清双解胶囊和片剂治疗急性上呼吸道感染(风温病热在肺卫证)的疗效,并对其安全性作出评价。方法:采用多中心随机对照双盲双模拟试验,对急性上呼吸道感染(风温病热在肺卫证)患者360例,按1∶1∶1比例随机分为一清双解胶囊组(治疗组A)120例,一清双解片剂组(治疗组B)120例及柴黄片组(对照组)120例。治疗组分别给予一清双解胶囊或片剂,每次3粒(片),每日3次;对照组给予柴黄片,每次3片,每日3次。疗程均为5d。观察治疗前后症状、体征变化和有无不良反应,并进行血、尿、大便常规,肝肾功能及心电图检查。结果:纳入患者360例,剔除3例,脱落18例,最终进入意向性(intention-to-treat,ITT)分析343例,符合方案集(per-protocol population set,PPS)分析339例。其中上呼吸道感染疗效:ITT显示,治疗组A总显效率84.96%,总有效率为96.46%;治疗组B分别为85.48%,97.45%;对照组分别为72.58%,99.12%。PPS显示,治疗组A总显效率87.27%,总有效率97.27%;治疗组B分别为86.20%,97.41%;对照组分别为72.58%,99.12%。试验组(胶囊、片剂)疾病疗效优于对照组(P<0.05),ITT与PPS结果一致。中医证候疗效:ITT显示,治疗组A愈显率84.07%,总有效率96.46%;治疗组B分别为88.89%,97.44%;对照组分别为72.58%,99.12%。PPS显示,治疗组A愈显率85.46%,总有效率97.27%;治疗组B分别为89.65%,97.41%;对照组分别为72.58%,99.12%。试验组(胶囊、片剂)中医证候疗效优于对照组(P<0.05),ITT与PPS结果一致。观察中未发现明显不良反应。结论:一清双解胶囊和片剂治疗急性上呼吸道感染热在肺卫证疗效确切,未发现明显毒副作用。
文摘Thirty-one herbal preparations produced and sold on the Ghanaian market were randomly purchased from sales outlets and analyzed for their microbiological quality by testing for the presence of total coliform bacteria, faecal coliform bac- teria, and total heterotrophic bacteria count. Also tested for was detection of pathogenic bacteria such as the Salmonella spp. and Clostridium spp. Opportunistic bacterial pathogens (Aeromonas spp., Enterococcus spp. and Pseudomonas spp.) and mould were also tested for. The herbal preparations tested came from different processing companies and in- cluded those labeled as suitable for treating arthritis, asthma, anaemia, diabetes mellitus, epilepsy, cough, hypertension, dysmenorrhoea, malaria, urine retention and loss of appetite. Aliquots of the various herbal products were cultured on various selective media. Eight (8) of the products showed the presence of all microorganism analyzed for including the pathogenic ones and are recommended not be used. Five (5) of the products did not have any microorganism present. Eleven (11) products showed the presence of only total heterotrophic bacteria and the values ranged from 1 to 94 cfu per ml. These two groups of total of sixteen (16) products can be used without any microbiological risk. Another three (3) products showed presence of only total heterotrophic bacteria but the values ranged from 118 to 1648 cfu per ml. Majority of the herbal preparations showed the presence of pathogenic bacteria. These three products may pose danger to the user can be used with caution. None of the herbal products recorded the presence of Enterococcus spp.
